Amneal Launches Boruzu for Multiple Myeloma and Mantle Cell Lymphoma

Amneal Pharmaceuticals Inc. and Shilpa Medicare Limited announced the U.S. launch of Boruzu, a new presentation of ...

APRIL 8, 2025

FDA Approves Calquence With Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma

The FDA has granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab ...

JANUARY 21, 2025

Hematopoietic Transplant Appears Superfluous in Many Mantle Cell Lymphoma Patients

In the context of high levels of response now being obtained in mantle cell lymphoma with modern induction and ...

JANUARY 2, 2025

FDA Approves Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

The FDA has approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, a Bristol Myers Squibb company) for ...

MAY 31, 2024

Combining Inhibitors of BTK and BCL-2 Improves Outcome in R/R Mantle Cell Lymphoma

By combining ibrutinib and venetoclax, which are two targeted oral therapies with different mechanisms of action, a ...

DECEMBER 19, 2023

Jaypirca Approved for Relapsed or Refractory Mantle Cell Lymphoma

The FDA granted accelerated approval to pirtobrutinib (Jaypirca, Lilly) for relapsed or refractory mantle cell ...

FEBRUARY 10, 2023

BTK Inhibitor Challenges Standard of Care in Younger Patients With MCL

Already widely considered a standard first-line treatment in older adults with mantle cell lymphoma (MCL), a Bruton ...

JANUARY 9, 2023

Relapsed/Refractory Mantle Cell Lymphoma: Promising Treatments on the Horizon

A rare and incurable form of non-Hodgkin lymphoma, mantle cell lymphoma (MCL) is a very heterogeneous disease that ...

NOVEMBER 21, 2022

Tecartus Approved as First CAR T-Cell Therapy for Mantle Cell Lymphoma

The FDA approved the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus, Kite) for ...

JULY 28, 2020

CAR-T Therapy Promising for BTK-Refractory Mantle Cell Lymphoma

A novel CAR T-cell therapy has shown encouraging results for patients with mantle cell lymphoma with disease ...

MAY 22, 2020

VR-CAP Beneficial in Transplant-Ineligible Untreated MCL Patients

Treatment with VR-CAP lengthens survival in patients with transplant-ineligible untreated mantle cell lymphoma ...

NOVEMBER 15, 2018

FDA Approves BTK Inhibitor Calquence for Mantle Cell Lymphoma

The FDA granted accelerated approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with ...

NOVEMBER 1, 2017